bioAffinity Technologies Reports Record Monthly Testing Volume in October for Its Noninvasive CyPath® Lung Test
Business Wire•11/11/2026•08:00 ET
0
Key Highlights
- ➤October testing volume reached record 235 CyPath Lung tests
- ➤October testing volume increased 29% versus October 2025
- ➤October volume equaled approximately 45% of Q3 2026 tests
- ➤bioAffinity expanded its sales team to increase CyPath Lung reach
Expert Statements
Maria Zannes, President and Chief Executive Officer of bioAffinity Technologies
“October’s testing volume reflects our efforts to expand the commercial reach of CyPath Lung”
bioAffinity Technologies Reports Record Monthly Testing Volume in October for Its Noninvasive CyPath® Lung Test
October testing volume equals approximately 45% of all tests performed in the previous quarter
Get started
Create a free account to read the full story.